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Abstract 
Objective: We describe the prevalence of pain and its associations with healthcare resource 
utilisation and quality-of-life. 
Design: The POPPY Study recruited three cohorts: older PLWH (≥50 years, n=699), younger 
demographically/lifestyle similar PLWH (<50 years, n=374) and older demographically/lifestyle 
similar HIV-negative (≥50 years, n=304) people from April 2013-February 2016.   
Methods: Current pain and pain-related healthcare use was collected via a self-reported 
questionnaire.  Logistic regression assessed between-group differences in the prevalence of pain in 
the past month and current pain after controlling for potential confounders.  Associations between 
current pain and healthcare resource use, reported joint problems, depressive symptoms, quality-of-
life and functional status were assessed in PLWH using Mann-Whitney U and Chi-squared tests. 
Results: Pain in the past month was reported by 473/676 (70.0%) older PLWH, 224/357 (62.7%) 
younger PLWH and 188/295 (63.7%) older HIV-negative controls (p=0.03), with current pain 
reported in 330 (48.8%), 134 (37.5%) and 116 (39.3%), respectively (p=0.0007). Older PLWH were 
more likely to experience current pain, even after adjustment for confounders.  Of those with pain in 
the past month, 56/412 (13.6%) had missed days of work or study due to pain, and 520 (59%) had 
seen a doctor about their pain.  PLWH experiencing current pain had more depressive symptoms, 
poorer quality-of-life on all domains, and greater functional impairment, regardless of age group.  
Conclusions: Even in the effective ART era, pain remains common in PLWH and has a major impact 
on quality-of-life and associated healthcare and societal costs.  Interventions are required to assist 
clinicians and PLWH to proactively manage pain. 
Word count: 250 
Key words: HIV; pain; quality of life; depressive symptoms 
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Introduction 
The widespread use of antiretroviral treatment (ART), and an increased focus on engagement and 
retention in care, has meant that people living with HIV (PLWH) in many parts of the world now have 
a near-normal life expectancy, particularly if a good CD4 cell count response and undetectable viral 
load are achieved on ART [1,2]. However, the cohort of PLWH is ageing: for example, recent data 
from the Netherlands suggest that by 2030, almost three-quarters of PLWH will be aged 50 years or 
older, with the prevalence of age-associated co-morbidities (such as cardiovascular disease, 
diabetes, chronic kidney disease, osteoporosis and non-AIDS malignancies) and use of concomitant 
medications also expected to increase [3].  
Moderate or severe pain has, in some studies, been reported to be one of the most common 
physical symptoms among PLWH, with reported prevalence ranging from 30% to 83% [4-8], and 
reports of high rates of several pain-related conditions among PLWH in Western countries [9-12].  
Pain among PLWH has both clinical and public health importance.  Not only is pain associated with 
psychological distress, emotional problems, poor quality-of-life and suicidal ideation [13-17], but it is 
also known to impact on activities of daily living [18] and is associated with higher rates of sick leave, 
job loss and lower satisfaction with health care [19].  Among PLWH, pain is associated with poorer 
adherence to ART [20, 21], higher rates of viral load rebound [22], treatment switching [23, 24] and, 
in some subgroups, missed clinic visits [25].  Furthermore, PLWH in pain are more likely to 
experience lack of social support [26] and to be involved in risky behaviours such as alcohol use, 
intravenous drug use and sexual risk taking [6, 27-30].  Thus, in addition to the burdens placed on 
both the individual and the healthcare/social system, pain in PLWH has the potential to seriously 
curtail attempts to eliminate new HIV infections.  
Despite this, chronic pain is, however, mostly neglected in clinical practice and little research has 
been conducted on the topic in the modern ART era among individuals in whom HIV infection is 
largely controlled.  Yet, effective interventions for pain are available which could lead to substantial 
benefits if used appropriately.  We describe the prevalence of pain, associated factors and 
association with healthcare resource utilisation and quality-of-life among PLWH and 
demographically and behaviourally similar HIV-negative controls.   
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Methods 
POPPY is a prospective cohort study at seven clinical sites in the UK and Ireland that aims to 
investigate the impact of HIV on the development and outcomes of comorbidities and 
pharmacotherapy among older PLWH [31]. Three sub-groups are studied within POPPY: older HIV-
positive (≥50 years old, n=699), younger HIV-positive (<50 years, n=374) and older HIV-negative (≥50 
years old, n=304) people.  Eligible HIV-positive participants acquired HIV through sexual transmission 
(either sex between men or sex between men and women – those acquiring HIV through other 
routes, including injection drug use, were excluded), were cisgender, and were either of white or 
black African ethnicity.  Those recruited to the younger group of PLWH were frequency-matched to 
the group of older PLWH on gender, ethnicity, sexual orientation and participating clinic.  HIV-
negative participants were required to have a documented negative HIV testing; this group was 
frequency-matched to the older PLWH group on age, gender, ethnicity, sexual orientation and 
geographical location (in or out of London).   The study was approved by the UK National Research 
Ethics Service (NRES; Fulham, London, UK; reference number 12/LO/1409) and written informed 
consent was obtained from all participants. 
The POPPY dataset includes information on socio-demographics, pharmacotherapy, family history, 
medical history, healthcare utilisation and quality-of-life. The POPPY dataset is linked to the UK 
Collaborative HIV Cohort (UK sites [32]) and to the UCD ID Cohort (Dublin [33]) for historic data on 
ART and longitudinal data on CD4 counts and HIV RNA.  A self-completed questionnaire [5] asks 
about experience of aches or pains that have lasted one day or longer in the past month, whether 
the pain is current, the bodily site of any pain, whether it has resulted in any missed days from work, 
or whether it has resulted in the participant consulting their family doctor; responses to each of 
these questions are either ‘yes’ or ‘no’.  Information on pain and related resource-use is also 
available through the data captured on concomitant medication use (including specific use of a 
range of analgesics, reported as free-text), self-reported medical conditions (including a history of 
joint problems, joint inflammation, rheumatoid/osteo-arthritis, joint replacement, aches/pains and 
back pain), and reported visits to the GP, pain clinics or other specialist services for reasons relating 
to pain over the past year.  Information on quality-of-life is collected via the SF-36 questionnaire 
[34], with depressive symptoms assessed through use of the Center for Epidemiologic Studies 
Depression (CES-D) questionnaire [35] (score >16 indicative of significant depression), and Patient 
Health Questionnaire-9 (PHQ-9) questionnaire [36] (score >5 indicative of current depression).  The 
Lawton Instrumental Activities of Daily Living (IADL) questionnaire [37] is used to assess functional 
status; participants are considered as fully functional if they have a score of >8 on this scale.  The 
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present analyses used cross sectional data from the baseline POPPY visit only, conducted between 
April 2013 and February 2016.   
Statistical analysis 
The proportions of participants in the three POPPY study groups reporting any aches and pains in the 
past month, and reporting current pain, were compared using Chi-squared tests and logistic 
regression, with and without adjustment for gender, sexuality, race, educational level and body mass 
index (BMI, calculated as weight/height2) all assessed at the baseline visit.  Although we also 
describe associations with working status, this was not incorporated into multivariable regression 
analyses due to the difficulties in assessing the direction of any association.  Associations of current 
pain with quality-of-life, depressive symptoms and IADL in the subgroup of PLWH were assessed 
using Mann Whitney U tests and Chi-squared tests, after stratification by age group (these analyses 
did not include the group of HIV-negative controls given the strong impact of HIV infection on these 
outcomes).  All analyses were performed using SAS v9.3 (SAS Institute Inc., Cary, NC).    
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Results 
Prevalence of pain 
Information on pain was available for 1325 of the 1377 (96.2%) POPPY participants (Table 1), 676 of 
older PLWH, 357 younger PLWH and 292 HIV-negative controls.  Those for whom information on 
pain was available were more likely to be male (81.1% vs. 65.4%, p=0.008), men who have sex with 
men (MSM, 70.6% vs. 53.9%, p=0.02), of white ethnicity (86.1% vs. 65.4%, p=0.0001), and had been 
recruited in the earlier years of the study (58.4% recruited in 2013/2014 vs. 44.2%, p=0.04).  
Furthermore, the median age of those with information on pain was slightly lower at 54 years vs. 51 
years in those without information on pain (p=0.05).  Among PLWH, 1011 (97.9%) of those with pain 
information available were on ART, 925 (90.0%) had a viral load <50 copies/ml, and median latest 
and nadir CD4 counts were 626 and 203 cells/mm3, respectively, with no significant differences from 
those without information available. 
The prevalence of reported aches and pains in the last month was 66.6% (882/1325) and was 
significantly higher in older PLWH (473/676, 70.0%) than in either younger PLWH (224/357, 62.7%) 
or older HIV-negative controls (188/295, 63.7%, p=0.03).  Those who reported pain in the past 
month were more likely to be female (p=0.01), heterosexual (p=0.02), of black African ethnicity 
(p=0.01) and were slightly older (p=0.01) than those not reporting pain (Table 1).  Those reporting 
pain in the past month also had lower educational attainment (p=0.002) than those not reporting 
pain in the past month. In unadjusted analyses, and compared to older PLWH, the odds of reporting 
aches or pains in the last month was 28% lower in younger PLWH, and 26% lower in HIV-negative 
controls (Figure 1a); after adjustment for potential confounding factors, associations between the 
three groups remained significant (Figure 1a).  
Of those reporting pain in the past month, pain was reported to be current in 580 (43.8% of those 
with information on pain, Table 1).  Current pain was again more common in the older PLWH 
(330/676, 48.8%) than in younger PLWH (134/357, 37.5%), or older HIV-negative controls (116/292, 
39.7%).  Associations with demographic factors, work and educational status were broadly similar to 
those seen for any pain in the past month.  In unadjusted analyses, and compared to older PLWH, 
the odds of reporting current pain was 37% lower in younger PLWH and 31% lower in HIV-negative 
controls (Figure 1b) with associations again remaining significant after adjustment for potential 
confounders (Figure 1b).   
In the two groups of PLWH, of the HIV factors, only a lower nadir CD4 count was associated with an 
increased risk of either pain in the past month or current pain in the two groups of PLWH, with no 
7 
 
associations being seen with either ART exposure or current CD4 count (Table 1).  Adjustment for 
nadir CD4 count did not modify the association between age group and either any pain in the past 
month or current pain in PLWH (Figures 1a/b). 
Impact of pain on daily activities and resource use 
Of those reporting pain who provided a response, 13.6% (56/412) reported having missed days of 
work or study due to the pain; 18.9% (30/159) in older PLWH, 12.2% (17/139) in younger PLWH and 
7.9% (9/114) in HIV-negative controls (p=0.03).  When we compared current work status, only 41.7% 
of those reporting current pain were working full-time, compared to 62.7% of those not reporting 
current pain.  Whilst similar (small) proportions in the two groups were students (1.4% vs. 1.1%, 
respectively), 30% of those reporting current pain were unemployed or on sick leave (vs. 14.8% in 
those not reporting current pain) and 26.9% were classified as having other or unknown work status 
(vs. 21.5% of those not reporting current pain, global p=0.0001).  Fifty-nine percent of participants 
had seen a doctor about their pain (295 (62.4%), 110 (49.1%) and 115 (62.2%) in the three groups 
respectively, p=0.002).  Pain-related resource use is shown in Table 2.  Reported analgesic use was 
more common in older PLWH than in the other two groups.  Although there were significant 
between-group differences in reported joint problems, GP visits and any pain-related resource use, 
these differences appeared to be driven more by older age than by HIV status.  GP visits for pain 
were lower in the two groups of PLWH than in HIV-negative controls. 
PLWH experiencing current pain had significantly higher scores on both CES-D and PHQ-9, regardless 
of age group, reflecting greater levels of depressive symptoms (Table 3).  Almost all domains of 
quality-of-life were poorer in those experiencing current pain than in those without current pain.  
Individuals in both age groups experiencing current pain were also less likely to be classified as fully 
functional on the Lawton IADL score. 
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Discussion 
Despite the use of more modern ART regimens, older PLWH continue to experience higher rates of 
pain than similarly-aged HIV-negative participants.  Interestingly, whilst younger PLWH also reported 
a high rate of pain, this was at a similar level to that seen among the older HIV-negative participants.  
In all three groups, pain was associated with lower employment rates and with high levels of 
healthcare resource use.  Among the two groups of PLWH, current pain was associated with higher 
depressive symptoms, poorer quality-of-life and poorer functional status, regardless of age.   
Pain has frequently been reported to be one of the most common symptoms among PLWH, 
particularly in the pre- and early-combination ART eras.  In a review article of 28 studies published 
from 1993-2011, Parker [6] reported a weighted point prevalence of pain of 54% and a three-month 
pain prevalence rate of 83%.  Whilst more recent years have seen improvements in both the efficacy 
of ART, and the range of ART drugs that are available for use, pain continues to be frequently 
reported [4, 5, 8].  Among participants in the Women’s Interagency HIV Study (WIHS), 56.1% 
indicated experiencing pain for at least 6 days over the past 6 months, with one in ten participants 
reporting experiencing pain for >120 days and over a third reporting experiencing extreme pain at 
least once over the period [38].  Pain in PLWH is also complex; in one study of attendees at a primary 
care clinic in New York City [39], the most common pain disorders reported were musculoskeletal 
pain, followed by neuropathic pain, headaches (including migraine), other poorly defined pain 
syndromes and chronic pelvic pain; multiple chronic pain diagnoses are commonly reported [5, 40].  
Whilst it is tempting to attribute some of this high prevalence of pain to HIV infection, other causes 
may also be common – for example, among indigenous adults in San Francisco in the Research on 
Access to Care in the Homeless (REACH) study [41], physical assault and living conditions were 
commonly cited as causes of pain.   
Whilst we did not aim to identify specific risk factors for current pain, pain was more commonly 
reported in women who, in our study, were also more likely to have acquired HIV infection through 
sex with men and to be of black African origin, and in those of lower educational attainment.  
Associations with gender in the published literature have been inconsistent [4,6,41], but lower 
educational levels have been reported to be associated with an increased prevalence of pain [41].  
Older age is generally associated with an increased risk of pain as well as greater pain severity [5, 38, 
39], consistent with our own findings.  An association of pain with more advanced HIV infection (as 
expressed by lower current/nadir CD4 counts, higher HIV viral loads and/or longer duration of HIV 
infection) has been reported previously [4, 5, 38].  
9 
 
Findings regarding other pain-related markers were somewhat less consistent.   Whilst analgesic use 
was more common in older PLWH, joint problems occurred at a similar rate in both older groups in 
our study.  Although a high proportion of participants had consulted a doctor about their pain (with 
no large differences between the two older groups in the study), visits to the GP for pain-related 
reasons were, if anything, more common in older HIV-negative controls, likely reflecting the fact that 
PLWH in the UK are under close management at their HIV clinic and are more likely to consult their 
HIV consultant for issues relating to pain than they are to consult a GP (HIV care in the UK is 
generally provided by hospital specialists). Other studies have reported high rates of healthcare 
resource use due to pain [5, 39, 42].  In a study of 103 people with HIV-related neuropathic pain [42], 
participants had been prescribed an average of 0.7 non-prescription pain-related medications 
(antiepileptics and opioids being most common) over the past 4 weeks with around 20% having 
received 3 or more such medications.  Among primary care attendees in New York City [39], those 
reporting chronic pain had more emergency department visits and more radiology procedures with a 
trend towards a greater number of inpatient admissions.  These studies did not generally make 
comparisons to a similar HIV-negative control group, and therefore it is unclear whether pain-related 
resource use in PLWH is any higher than would be expected in a similarly aged group in the general 
population. In one study of veterans with and without HIV in the United States [43], 13% of 
participants reported nonmedical use of prescription opioids, although in adjusted analyses no 
association was reported with HIV status.  
Whilst only a small proportion of participants reported missing days of work or study due to pain, 
those with pain were less likely to be in full-time work and more likely to be unemployed or off sick 
than those without pain.  An impact on work has been reported in other studies: Mann reported 
that among those with neuropathic pain, there was a 36.1% overall work impairment due to the pain 
which increased with increasing pain severity [42].  Total unadjusted annualized costs due to HIV-
related neuropathic pain ranged from $9,900 to $25,822 per person, depending on the severity of 
the pain.   
Among PLWH, we noted strong associations between the presence of pain and depressive 
symptoms, quality-of-life and functional impairment, regardless of age, as reported in other studies 
[5, 8, 42, 44].  Merlin [17] reported that current pain was associated with impairments in mobility, 
self-care and usual activities.  A causal association between pain and interference with daily 
activities is supported by findings from a randomised trial of a pain education intervention, in which 
those randomised to the intervention experienced reduced pain interference with daily activities 
after an 8-week period [45].  Associations with substance use have also been reported [8, 38, 39], 
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with pain serving both as a mediator and as a predictor of more use of recreational drugs, as well as 
more depressive symptoms [46].  Other negative effects of pain include direct associations with 
reduced social support [26] and with higher rates of unprotected vaginal or anal sex [29], raising 
concern that pain in PLWH may also lead to worse outcomes on ART.  Whilst we were unable to 
consider this association in our cross-sectional analysis (the majority of POPPY participants were on 
stable ART at recruitment), Surratt [7] reported that those with untreated pain had a 42% lower 
odds of 95% medication adherence in the previous week compared to those who were pain-free. 
As yet, the mechanisms by which HIV may lead to an increased risk of pain remain unclear.  In 2013, 
Merlin [47] proposed a conceptual biopsychosocial framework for understanding chronic pain in 
PLWH, which includes biological (such as HIV neuropathy), psychological (following traumatic 
events) and social (environmental and relationship) factors.  More recently [48], Merlin noted 
significantly higher levels of IL-1 a marker already implicated in a range of inflammatory and 
autoimmune diseases, in PLWH with chronic pain than in those without chronic pain, suggesting a 
biological pathway. Thus, interventions to reduce the burden of pain in this population need to 
address both physical and psychological factors. Whilst there is some evidence to suggest that self-
management interventions may be effective in improving pain and physical symptoms, the quality of 
evidence to support these interventions is relatively poor [49].  A recent pilot study [50] has, 
however, demonstrated feasibility and acceptability of such an approach.  
The large sample of PLWH in our study is broadly representative of older PLWH in western European 
settings, where the population is optimally treated for their HIV (with high levels of viral 
suppression).  This has allowed us to describe the prevalence of pain among PLWH in an era of very 
effective treatment.  In comparison to many earlier studies, our study also benefits from the 
inclusion of appropriately selected HIV-negative controls with similar characteristics to the older 
PLWH in the study, allowing us to determine the role of HIV infection in the development of pain.  
Indeed, our study also reports a high prevalence of pain in older HIV-negative people from a similar 
demographic background and with similar lifestyles – thus, the contribution of HIV itself to the high 
reported rate of pain in PLWH may be less than widely thought, with other contributory causes 
being common in this age group.  However, some limitations must be noted.  Firstly, whilst the 
POPPY study is a prospective cohort, the analyses reported herein relate to the baseline visit only 
limiting inferences around causality - future analyses of the longitudinal follow-up of this cohort will 
permit more detailed analyses of the impact of pain on longer-term general and health-related 
outcomes as well as the identification of predictors (both HIV-related and HIV-unrelated) of incident 
and chronic pain.  Due to the observational nature of the study, we cannot rule out the possibility 
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that unmeasured common causes of pain and negative health outcomes may exist, which may 
introduce confounding. Whilst our cohort is broadly representative of the older population of PLWH 
in the UK and Ireland, the fact that most participants are engaged in care and are on stable ART may 
have introduced some selection bias; equally, this population may represent a cohort that has 
‘survived’ through earlier eras of ART and may not be representative of those who are infected with 
HIV in more recent years.   
Conclusions 
Our study confirms that even in the era of effective ART, and in individuals with largely controlled 
HIV infection, pain remains common among PLWH with major impact on quality-of-life and 
associated healthcare and societal costs.  Interventions are required to assist clinicians to proactively 
manage pain in their patients, and to assist PLWH to communicate their pain to clinicians and to self-
manage pain and related symptoms. Our findings support the need for routine assessment of pain in 
this group.  Further longitudinal studies of the severity, location and contributors to pain in PLWH 
will support the development of effective, low cost and easy to manage interventions for pain 
management.  
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Table 1: Characteristics of a) all POPPY participants included in the analysis of pain data, b) those who do and do not report pain in the last month, and c) 
those who do and do not report current pain; table entries show n and column percentages, unless otherwise stated 
  Total with pain 
data 
Aches or pains in the last month P-
value* 
Current pain P-
value*   Yes No Yes No 
Number of participants 1325 (100.0) 882 443  580 745  
 
Cohort Older HIV-positive 676 (51.0) 473 (53.6) 203 (45.8)  330 (56.9) 346 (46.4) 
 
 Younger HIV-positive 357 (26.9) 224 (25.4) 133 (30.0)  134 (23.1) 223 (29.9)  
 Older HIV-negative 292 (22.0) 188 (21.0) 107 (24.2) 0.03 116 (20.0) 176 (23.6) 0.0007 
Gender Male 1075 (81.1) 698 (79.1) 377 (85.1)  455 (78.5) 620 (83.2) 
 
 Female 250 (18.9) 184 (20.9) 66 (14.9) 0.01 125 (21.6) 125 (16.8) 0.03 
Sexuality/risk group MSM 935 (70.6) 603 (68.4) 332 (74.9)  397 (68.5) 538 (72.2) 
 
 Heterosexual 390 (29.4) 279 (31.6) 111 (25.1) 0.02 183 (31.6) 207 (27.8) 0.15 
Race White 1141 (86.1) 744 (84.4) 397 (89.6)  490 (84.5) 651 (87.4) 
 
 Black African 184 (13.9) 138 (15.7) 46 (10.4) 0.01 90 (15.5) 94 (12.6) 0.15 
Education O levels or lower 341 (25.7) 253 (28.7) 88 (19.9)  177 (30.5) 164 (22.0) 
 
 A levels 193 (14.6) 122 (13.8) 71 (16.0)  77 (13.3) 116 (15.6)  
 Higher than A levels/unknown 791 (59.7) 507 (57.5) 284 (64.1) 0.002 326 (56.2) 405 (62.4) 0.002 
Age (years) Median (IQR) 54 (49, 60) 54 (49, 60) 53 (48, 59) 0.01 55 (50, 60) 53 (48, 59) 
0.0005 
BMI (kg/m2) Median (IQR) 25.7 (23.3, 
28.6) 
25.9 (23.3, 
28.9) 
25.4 (23.3, 
28.0) 
0.07 26.0 (23.6, 
29.1) 
25.4 (23.1, 
28.2) 
0.0009 
Year of baseline visit 2013 187 (14.1) 116 (13.2) 71 (16.0)  78 (13.5) 109 (14.3) 
 
 2014 587 (44.3) 406 (46.0) 181 (40.9)  283 (48.8) 304 (40.8)  
 2015 497 (37.5) 324 (36.7) 173 (39.1)  197 (34.0) 300 (40.3)  
 2016 54 (4.1) 36 (4.1) 18 (4.1) 0.27 22 (3.8) 32 (4.3) 0.03 
HIV-positive cohorts only         
Current CD4 (cells/mm3) Median (IQR) 626 (478, 810) 630 (477, 816) 607 (479, 806) 0.49 624 (473, 809) 626 (479, 810) 0.94 
Nadir CD4 (cells/mm3) Median (IQR) 203 (102, 306) 200 (87, 300) 218 (128, 332) 0.004 185 (85, 290) 217 (120, 324) 0.0009 
On antiretroviral therapy  1011 (97.9) 682 (97.9) 329 (97.9) 1.00 456 (98.3) 555 (97.5) 0.55 
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Viral load <50 copies/ml  925 (89.9) 629 (90.6) 296 (88.4) 0.31 424 (92.0) 501 (88.2) 0.06 
* P-value obtained from Chi-squared test (categorical covariates) or Mann-Whitney U test (continuous covariates) 
MSM: men who have sex with men; IQR: interquartile range. 
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Figure 1: Results from univariate and multivariable analyses to identify predictors of a) any aches or 
pains in the past month and b) current pain 
a) Any aches or pains in the past month 
 
 
 
b) Current pain 
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Table 2: Other markers of pain assessed as part of the baseline POPPY study visit, stratified by study group 
  Group  
 Overall Older HIV-
positive 
Younger HIV-
positive 
Older HIV-
negative 
p-value (Chi-
squared test) 
Number of participants 1377 699 374 304  
Concomitant medication      
Any reported analgesic use 210 (15.3) 130 (18.6) 49 (13.1) 31 (10.2) 0.001 
Reported health problems 
     
Any joint problem 629 (45.7) 371 (53.1) 108 (28.9) 150 (49.3) 0.0001 
Resource use 
     
GP – generalised pain 22 (1.6) 10 (1.4) 7 (1.9) 5 (1.6) 0.86 
GP – back pain 65 (4.7) 28 (4.0) 16 (4.3) 21 (6.9) 0.12 
GP – joint pain problems 104 (7.6) 50 (7.2) 21 (5.6) 33 (10.9) 0.03 
GP – other pain 112 (8.1) 58 (8.3) 27 (7.2) 27 (8.9) 0.71 
Any GP visit for pain-related reasons 264 (19.2) 128 (18.3) 59 (15.8) 77 (25.3) 0.005 
Any GP visits 1052 (76.4) 547 (78.3) 260 (69.5) 245 (80.6) 0.0009 
Median (range) number of GP visits 2 (1-32) 2 (1-32) 2 (1-23) 2 (1-20) 0.09 
Other specialist – pain management 19 (1.4) 14 (2.0) 2 (0.5) 3 (1.0) 0.12 
Any pain-related resource use 274 (19.9) 136 (19.5) 59 (15.8) 79 (26.0) 0.004 
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Table 3: Association between current pain, depression scores (CES-D, PHQ9) and components of quality-of-life (SF-36) among PLWH, stratified by age group 
 PLWH aged >50 years p-value2 PLWH aged <50 years p-value2 
 No current pain Current pain No current pain Current pain 
Depressive symptoms1       
CES-D score, median (IQR) 9 (3, 17) 15 (7, 26) 0.0001 7 (3, 15) 14 (7, 27) 0.0001 
Significant depression (>16), n (%)  92 (28.5) 148 (50.0) 0.0001 51 (24.6) 57 (46.3) 0.0001 
PHQ-9 score, median (IQR) 2 (0, 7) 7 (2, 12) 0.0001 3 (1, 7) 6 (2, 13) 0.0001 
Current depression (>5), n (%) 120 (36.6) 183 (60.2) 0.0001 85 (39.9) 73 (57.5) 0.002 
Quality of life (SF-36 subscales)1, median (IQR)       
Physical functioning 90 (75, 100) 72 (45, 90) 0.0001 100 (95, 100) 90 (55, 100) 0.0001 
Role limitations due to physical health 100 (50, 100) 50 (0, 100) 0.0001 100 (100, 100) 75 (0, 100) 0.0001 
Role limitations due to emotional problems 100 (33, 100) 83 (0, 100) 0.0002 100 (66, 100) 67 (0, 100) 0.0001 
Energy/fatigue 65 (50, 80) 50 (25, 65) 0.0001 65 (50, 80) 50 (30, 65) 0.0001 
Emotional well-being 80 (60, 88) 68 (52, 84) 0.0001 80 (60, 88) 68 (52, 84) 0.001 
Social functioning 90 (65, 100) 67 (42, 90) 0.0001 90 (67, 100) 67 (42, 90) 0.0001 
General health 70 (55, 80) 50 (30, 70) 0.0001 75 (55, 85) 60 (40, 75) 0.0001 
Lawton Instrumental Activities of Daily Living       
Fully functioning, n (%) 302 (91.0) 241 (76.5) 0.0001 205 (95.4) 98 (77.2) 0.0001 
1For CES-D and PHQ-9, higher values indicate greater depressive symptoms; for the sub-scales of the SF-36, lower values indicate poorer quality of life. 2p-values obtained from Mann-Whitney 
U test (numerical outcomes) or Chi-squared test (categorical outcomes) 
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